Should I buy or sell OncoCyte stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OCX shares. View OCX analyst ratings or view top-rated stocks .

What is OncoCyte's stock price target for 2024?

4 brokerages have issued 1-year target prices for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they expect the company's stock price to reach $3.90 in the next twelve months. This suggests a possible upside of 52.3% from the stock's current price. View analysts price targets for OCX or view top-rated stocks among Wall Street analysts .

How have OCX shares performed in 2024?

OncoCyte's stock was trading at $2.50 at the beginning of the year. Since then, OCX stock has increased by 2.4% and is now trading at $2.56. View the best growth stocks for 2024 here .

When is OncoCyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our OCX earnings forecast .

How were OncoCyte's earnings last quarter?

OncoCyte Co. (NASDAQ:OCX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($3.00) EPS for the quarter, missing the consensus estimate of ($2.40) by $0.60. The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $3.20 million. OncoCyte had a negative net margin of 3,923.58% and a negative trailing twelve-month return on equity of 77.26%.

When did OncoCyte's stock split?

OncoCyte's stock reverse split on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of OncoCyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV) , Biocept (BIOC) , CymaBay Therapeutics (CBAY) , Fulcrum Therapeutics (FULC) , Xeris Biopharma (XERS) , Zynerba Pharmaceuticals (ZYNE) , AbbVie (ABBV) , Acasti Pharma (ACST) and Aileron Therapeutics (ALRN) .

How do I buy shares of OncoCyte?

Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OCX

OncoCyte (OCX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free OCX Stock Alerts

$2.56

-0.03 (-1.16%)

(As of 05:17 PM ET)

Compare

Today's Range: $2.49
▼
$2.66
50-Day Range: $2.53
▼
$3.07
52-Week Range: $2.08
▼
$6.20

Volume: 36,692 shs
Average Volume: 48,313 shs
Market Capitalization: $21.15 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.90

Get OncoCyte alerts:

OncoCyte MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 52.3% Upside
$3.90 Price Target
Short Interest: Bearish
2.36% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.19
Based on 23 Articles This Week
Insider Trading: Acquiring Shares
$7.18 M Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.73 out of 5 stars

Medical Sector

621st out of 919 stocks

Diagnostic Substances Industry

8th out of 10 stocks

3.3

Analyst's Opinion

Consensus Rating
OncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
OncoCyte has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
2.36% of the float of OncoCyte has been sold short.
Short Interest Ratio / Days to Cover
OncoCyte has a short interest ratio ("days to cover") of 21.3, which indicates bearish sentiment.
Change versus previous month
Short interest in OncoCyte has recently increased by 0.45%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
OncoCyte does not currently pay a dividend.
Dividend Growth
OncoCyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OCX.

2.9

News and Social Media Coverage

News Sentiment
OncoCyte has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 23 news articles for OncoCyte this week, compared to 1 article on an average week.
Search Interest
4 people have searched for OCX on MarketBeat in the last 30 days.
MarketBeat Follows
3 people have added OncoCyte to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, OncoCyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,176,400.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 1.94% of the stock of OncoCyte is held by insiders.
Percentage Held by Institutions
55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Price to Book Value per Share Ratio
OncoCyte has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

The Next Nvidia?

The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.

Go here now for this breaking story.

About OncoCyte Stock (NASDAQ:OCX)

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

OCX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OCX Stock News Headlines

April 16, 2024 | insidertrades.com

OncoCyte Co. (NASDAQ:OCX) CEO Buys $10,000.50 in Stock

April 18, 2024 | americanbankingnews.com

OncoCyte (NASDAQ:OCX) Now Covered by StockNews.com

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

April 16, 2024 | americanbankingnews.com

OncoCyte Co. (NASDAQ:OCX) CEO Josh Riggs Buys 3,390 Shares

April 16, 2024 | americanbankingnews.com

OncoCyte Co. (NASDAQ:OCX) Director Andrew Arno Acquires 33,898 Shares of Stock

April 16, 2024 | americanbankingnews.com

OncoCyte (NASDAQ:OCX) Given Speculative Buy Rating at Benchmark

April 16, 2024 | americanbankingnews.com

OncoCyte Co. (NASDAQ:OCX) Major Shareholder Broadwood Partners, L.P. Buys 2,420,000 Shares of Stock

April 13, 2024 | seekingalpha.com

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

April 18, 2024 | InvestorPlace (Ad)

The Next Nvidia?

April 13, 2024 | finance.yahoo.com

Q4 2023 OncoCyte Corp Earnings Call

April 12, 2024 | investorplace.com

OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023

April 12, 2024 | msn.com

Top 3 Health Care Stocks That May Collapse In Q2

April 12, 2024 | finanznachrichten.de

OncoCyte Corporation: Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

April 12, 2024 | msn.com

S&P Futures Tick Lower as Investors Digest Big Bank Earnings

April 12, 2024 | msn.com

S&P Futures Tick Lower as Investors Cautiously Await U.S. Big Bank Earnings

April 12, 2024 | msn.com

Oncocyte announces $15.8 mln private placement of securities

April 12, 2024 | globenewswire.com

Oncocyte Reports Full Year 2023 Financial Results

April 11, 2024 | globenewswire.com

Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules

April 11, 2024 | globenewswire.com

Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay

April 11, 2024 | markets.businessinsider.com

Here's what Wall Street expects from Oncocyte's earnings

April 9, 2024 | globenewswire.com

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

February 29, 2024 | msn.com

NeuroBo stock jumps 14% on weight-loss drug update

February 24, 2024 | benzinga.com

OncoCyte Stock (NASDAQ:OCX), Short Interest Report

January 16, 2024 | finance.yahoo.com

Oncocyte to Present at the Sequire Investor Summit in Puerto Rico

January 7, 2024 | markets.businessinsider.com

BTIG Reaffirms Their Hold Rating on OncoCyte (OCX)

December 11, 2023 | benzinga.com

OncoCyte Stock (NASDAQ:OCX) Dividends: History, Yield and Dates

December 6, 2023 | finance.yahoo.com

Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays

See More Headlines

Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Diagnostic substances
Sub-Industry: N/A
Current Symbol: NASDAQ:OCX
CUSIP: N/A
CIK: 1642380
Web: oncocyte.com
Phone: (949) 409-7600
Fax: 510-521-3389
Employees: 75
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $3.90
High Stock Price Target: $5.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +50.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,780,000.00
Net Margins: -3,923.58%
Pretax Margin: -1,427.20%
Return on Equity: -77.26%
Return on Assets: -33.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.11
Quick Ratio: 2.11

Sales & Book Value

Annual Sales: $1.50 million
Price / Sales: 14.26
Cash Flow: $0.84 per share
Price / Cash Flow: 3.08
Book Value: $5.78 per share
Price / Book: 0.45

Miscellaneous

Outstanding Shares: 8,260,000
Free Float: 8,101,000
Market Cap: $21.39 million
Optionable: No Data
Beta: 0.80

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Joshua Riggs (Age 41)
President, CEO & Director
Comp: $373.2k
Mr. James Liu (Age 28)
Senior Director, Controller, Principal Accounting Officer & Interim Principal Financial Officer
Comp: $192.48k
Dr. Ekkehard Schutz M.D.
Ph.D., Chief Science Officer
Mr. Peter Hong
VP, General Counsel & Secretary
Mr. Yuh-Min Chiang Ph.D.
Senior Vice President of R&D and Product Development
Ms. Sandra O'Donald
Senior Vice President of Business Operations
Dr. Michael D. West Ph.D. (Age 71)
Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc.
Ms. Sara Riordan
Director of Medical Education

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OCX Stock Analysis - Frequently Asked Questions

Should I buy or sell OncoCyte stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" OCX shares.
View OCX analyst ratings or view top-rated stocks.
What is OncoCyte's stock price target for 2024?: 4 brokerages have issued 1-year target prices for OncoCyte's shares. Their OCX share price targets range from $3.00 to $5.00. On average, they expect the company's stock price to reach $3.90 in the next twelve months. This suggests a possible upside of 52.3% from the stock's current price.
View analysts price targets for OCX or view top-rated stocks among Wall Street analysts.
How have OCX shares performed in 2024?: OncoCyte's stock was trading at $2.50 at the beginning of the year. Since then, OCX stock has increased by 2.4% and is now trading at $2.56.
View the best growth stocks for 2024 here.
When is OncoCyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our OCX earnings forecast.

How were OncoCyte's earnings last quarter?: OncoCyte Co. (NASDAQ:OCX) issued its quarterly earnings results on Tuesday, November, 9th. The company reported ($3.00) EPS for the quarter, missing the consensus estimate of ($2.40) by $0.60. The company had revenue of $0.98 million for the quarter, compared to analyst estimates of $3.20 million. OncoCyte had a negative net margin of 3,923.58% and a negative trailing twelve-month return on equity of 77.26%.
When did OncoCyte's stock split?: OncoCyte's stock reverse split on Tuesday, July 25th 2023. The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of OncoCyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other OncoCyte investors own include VBI Vaccines (VBIV), Biocept (BIOC), CymaBay Therapeutics (CBAY), Fulcrum Therapeutics (FULC), Xeris Biopharma (XERS), Zynerba Pharmaceuticals (ZYNE), AbbVie (ABBV), Acasti Pharma (ACST) and Aileron Therapeutics (ALRN).
How do I buy shares of OncoCyte?: Shares of OCX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

OncoCyte (OCX) Stock Price, News & Analysis

OncoCyte MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About OncoCyte Stock (NASDAQ:OCX)

OCX Stock Price History

OCX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

OCX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™